X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
Under the acquisition, Essential Pharma has acquired the rights to Colobreathe (colistimethate sodium), indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis, across European markets.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Colobreathe
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Essential Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2024
Details:
The financing will be used to fund the upcoming Phase 3 studies of ColiFin (colistimethate sodium), an inhaled antibiotic therapeutic for the management of chronic infections in cystic fibrosis patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Financing August 15, 2023
Details:
The net proceeds from the capital commitment will enable the initiation of the Phase 3 COPILOT study, the first part of the registrational clinical studies planned for ColiFin, an inhaled therapeutic for the management of chronic infections in cystic fibrosis patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 18, 2023
Details:
This collaboration is expected to provide capitalization through significant clinical milestones in ColiFin®’s Phase 3 development. ColiFin® (colistimethate sodium) is being developed for the treatment of chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Genetic Disease Product Name: ColiFin
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 08, 2023
Details:
Colistimethate sodium (CMS) is a pro-drug (the form used for inhalation therapy) of the antibiotic colistin. Colistin is a polymyxin antibiotic derived from Bacillus polymyxa var. colistinus.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
Promixin (Colistimethate Sodium) is an investigational treatment being developed as a potential first-in-class inhaled therapy for adult patients with NCFB colonized with P. aeruginosa; NCFB is a chronic, progressive, and irreversible respiratory disease.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Data shows inhalation via the I-neb ® Adaptive Aerosol Delivery System of Promixin (colistimethate sodium) results in reduction of pulmonary exacerbations in non-cystic fibrosis bronchiectasis (NCFB) patients compared to placebo.
Lead Product(s): Colistimethate Sodium
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Promixin
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
